Business Context and Reporting Period
This Form 8-K was filed by Pharmacyte Biotech, Inc. on October 14, 2020. The report details a change in executive leadership and compensation arrangements effective September 1, 2020.
Key Financial Metrics
The filing does not provide financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial figure disclosed is the amended annual base salary for Dr. Gerald W. Crabtree, set at $84,000.
Material Changes
- Executive Role Change: Dr. Gerald W. Crabtree transitioned from Chief Operating Officer to Chief Scientific Officer.
- Compensation Adjustment: Dr. Crabtree's annual base salary was amended to $84,000 under Amendment No. 3 to his Executive Compensation Agreement.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on future operations, or discussion of risks and contingencies. The document is strictly limited to reporting the amendment of an executive agreement.
Investor Verification Checklist
- Verify the full text of Amendment No. 3 (Exhibit 10.1) for complete terms of the compensation agreement.
- Confirm the effective date of the role change (September 1, 2020) versus the filing date (October 14, 2020).
- Review subsequent filings for any financial impact of the executive transition.